Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

NCCN Guideline Adherence Spotty in These Patients

Am J Hematol; ePub 2017 Aug 17; Goldberg, et al

National Comprehensive Cancer Network recommendations for monitoring response to tyrosine kinase inhibitors (TKI) treatment are not being consistently followed in patients with chronic phase-chronic myeloid leukemia (CP-CML), according to an international observational study involving >1,200 individuals. Participants had CP-CML and received first-line treatment with TKIs. Investigators looked at use and management patterns in the US and Europe. Among the results:

  • 8 in every 10 patients had baseline comorbidities.
  • Monitoring for either cytogenetic or molecular responses (CyR/MR) improved over time.
  • 36% were monitored at 3 months; 82% at 6 months; and 95% at 1 year.
  • 5% had no record of CyR/MR monitoring in the first year of therapy.
  • Documentation of CyR/MR testing was lower in the US than in Europe.
  • It was also lower in community vs academic practices.
  • Patients <65 years of age, treated at academic centers, and no longer on first-line therapy were more likely to be monitored by 1 year.

Citation:

Goldberg S, Cortes J, Gambacorti-Passerini C, et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. [Published online ahead of print August 17, 2017]. Am J Hematol. doi:10.1002/ajh.24887.